[
  {
    "ts": "2024-12-13T18:57:24+00:00",
    "headline": "Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst",
    "summary": "BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead",
    "url": "https://finance.yahoo.com/news/despite-higher-valuations-life-sciences-185724901.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "a4d97f6a-d403-3bba-82ea-b23a400740c4",
      "content": {
        "id": "a4d97f6a-d403-3bba-82ea-b23a400740c4",
        "contentType": "STORY",
        "title": "Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst",
        "description": "",
        "summary": "BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead",
        "pubDate": "2024-12-13T18:57:24Z",
        "displayTime": "2024-12-13T18:57:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/d340fe96fb6e0ba350207d6be38ae4ff",
          "originalWidth": 885,
          "originalHeight": 498,
          "caption": "Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JeFiasvyy4Uu0Wl1c6wHGw--~B/aD00OTg7dz04ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d340fe96fb6e0ba350207d6be38ae4ff.cf.webp",
              "width": 885,
              "height": 498,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BduLOOGdeDkxPzyQbFMP3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d340fe96fb6e0ba350207d6be38ae4ff.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/despite-higher-valuations-life-sciences-185724901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/despite-higher-valuations-life-sciences-185724901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DHR"
            },
            {
              "symbol": "RVTY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]